Predictions
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€126.00
06.09.20
06.09.20
€155.00
04.11.21
04.11.21
28.41%
05.11.20
05.11.20
Medium risks for its business
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€155.40
20.08.20
20.08.20
-
05.09.20
05.09.20
-18.92%
05.09.20
05.09.20
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€150.60
18.08.20
18.08.20
€210.00
04.11.21
04.11.21
29.61%
22.01.21
22.01.21
Fair valuation
Known brand
Growths faster than the competition
Revenue growth >5% per year expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€98.00
20.05.20
20.05.20
€200.00
20.08.20
20.08.20
58.16%
20.08.20
20.08.20
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€63.20
07.04.20
07.04.20
€100.00
20.05.20
20.05.20
55.06%
20.05.20
20.05.20
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€40.55
17.03.20
17.03.20
€180.00
04.11.21
04.11.21
268.43%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€51.30
06.03.20
06.03.20
€85.00
07.04.20
07.04.20
23.20%
07.04.20
07.04.20
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€36.50
15.10.19
15.10.19
€50.00
04.11.21
04.11.21
309.32%
05.11.21
05.11.21
Shop Apotheke Europe NV
Start price
Target price
Perf. (%)
€34.30
05.10.19
05.10.19
€55.00
06.03.20
06.03.20
53.35%
06.03.20
06.03.20
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected